TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04617444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study: NCT03542747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Time to ventilation with the iLTS
Description: Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Time to ventilation with the iLTS
Description: Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Time to ventilation with the Fastrach
Description: Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Time to ventilation with the Fastrach
Description: Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
Study: NCT00743028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
Study: NCT02609074

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive internal fixation surgeries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive internal fixation surgeries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPC/rhBMP-2 micro-scaffolds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPC paste
Study: NCT02006329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Study: NCT00400699

Intervention type: OTHER
Group type: OTHER
Intervention: counseling intervention

Intervention type: OTHER
Group type: OTHER
Intervention: study of socioeconomic and demographic variables
Study: NCT03087760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Concurrent Pembrolizumab after proton reirradiation
Study: NCT01898728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical povidone-iodine after premedication with topical liquid eye drops
Study: NCT00400699

Intervention type: PROCEDURE
Group type: OTHER
Intervention: psychosocial assessment and care
Study: NCT04493567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days
Study: NCT00506584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk and pasteurized human milk fortifier
Description: Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk and pasteurized human milk fortifier
Description: Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk fortifier (bovine-based), pre-term formula
Description: Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk and pasteurized human milk fortifier
Description: Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-term/term formula
Description: Bovine milk-derived nutrition formulated for very low birth weight infants
Study: NCT03951025

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin oral administration
Description: One tablet with1 mg of melatonin and 82 mg of excipients
Study: NCT01898728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical povidone-iodine after premedication with topical gel
Study: NCT03951025

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin sublingual administration
Description: One tablet with 1 mg of melatonin and 82 mg of excipients
Study: NCT04020783

Intervention type: OTHER
Intervention: NO Intervention
Description: NO Intervention
Study: NCT01776931

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysine intake
Description: Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study: NCT00026299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT01377012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
Study: NCT00819637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arformoterol (RR formoterol)
Description: Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.~Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
Study: NCT00743028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
Study: NCT03336372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picato
Description: Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
Study: NCT04237038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic Nissen fundoplication short gastric vessel division
Description: Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
Study: NCT03808753

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion test (EEOT)
Description: The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini fluid challenge (mFC)
Description: The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
Study: NCT03289221

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anal Manometry
Description: A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry.
Study: NCT02370641

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PomX
Description: 1000 mg POMx daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PomX
Description: 1000 mg POMx daily for 4 weeks
Study: NCT00723346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: 50 UI/Kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: 100 UI/Kg
Study: NCT00819637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arformoterol (RR formoterol)
Description: Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.~Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levalbuterol
Description: Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
Study: NCT01061268

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: No topical artificial tear
Description: 40 patients randomized to not using a topical artificial tear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink® Tears Lubricant Eye Drops
Description: Blink® Tears Lubricant Eye Drops
Study: NCT06408506

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Re-Entry Surgery
Description: Re-entry surgery 4 months after the insertion of the implants to reveal implants after osseointegration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Probing peri-implant bone
Description: Probing peri-implant bone with Dental Probe during surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scanning peri-implant bone
Description: Scanning peri-implant bone during surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Impressions
Description: Conventional Impressions during surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implant Surgery
Description: Placement of 6 implants in the edentulous mandible

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Healing procedure
Description: All 6 Implants in all patients are let to heal for 4 Months under the same conditions:~The most distal implants are left submerged. The most mesial implants are left transgingival and the Implants in the middle are immediately loaded using gold bar retained dentures
Study: NCT01866046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESPECT-IPV
Description: rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
Study: NCT05746598

Intervention type: DRUG
Intervention: Cisplatin injection
Description: Cisplatin 75mg/m2

Intervention type: DRUG
Intervention: Cisplatin injection
Description: Cisplatin 75mg/m2
Study: NCT00723346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: 150 UI/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: native L asparaginase
Description: 10000UI/m2, 14 infusions during 4 chemotherapy cycle
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel
Study: NCT03159689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Tree Nuts
Description: Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pretzels
Description: Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
Study: NCT02699450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered by IVT injection in the study eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered by IVT injection in the study eye.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab will be administered by IVT injection in the study eye.
Study: NCT01663428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sup-ER Splint

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Currently accepted treatment
Study: NCT02496845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VL#FIA3-30
Description: Vasoactive dual treatment (MH30-01 \& IS045-01)
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel
Study: NCT02399956

Intervention type: OTHER
Intervention: Survey
Description: Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
Study: NCT02010866

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: counseling
Description: in-person counseling through RFWP offered to distressed respondents on the ISP and others who seek counseling (due to other reasons for referral)
Study: NCT04181385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 milligram
Description: Oral olanzapine capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 milligram
Description: Oral olanzapine capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine 5 milligram
Description: Oral bromocriptine capsule
Study: NCT00589927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
Study: NCT00950131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of information about drug approval and level of warning
Description: Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of information about drug approval and level of warning
Description: Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of information about drug approval and level of warning
Description: Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
Study: NCT04495881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg
Description: Sitagliptin 100mg Qd
Study: NCT00715624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: Dose to be kept stable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basal Insulin
Description: Dose to be kept stable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study: NCT00513136

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group based mind body medicine intervention
Description: Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based mind body medicine intervention + family focus
Description: In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
Study: NCT03007238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: Undergo ECP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04181385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: oral placebo capsules
Study: NCT01769716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation
Study: NCT03973515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucokinase activator
Description: PB-201 is a kind of dual and partial GKA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucokinase activator
Description: PB-201 is a kind of dual and partial GKA
Study: NCT03973307

Intervention type: DIAGNOSTIC_TEST
Intervention: UroX bladder cancer biomarker test
Description: Urine test using novel UroX biomarker test for bladder malignancy
Study: NCT03973515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucokinase activator
Description: PB-201 is a kind of dual and partial GKA
Study: NCT02724475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LA
Description: Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D-CRT
Description: γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
Study: NCT02416440

Intervention type: OTHER
Intervention: blood sample
Description: blood sample
Study: NCT03973515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet
Study: NCT02177643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacerein
Description: Diacerein oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules
Study: NCT03547154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Description: Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alfa-2b
Description: Daily SC injection of interferon alfa-2b, 5 MIU/m\^2
Study: NCT03316274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given via intralesional injection
Study: NCT05454059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.
Study: NCT03316274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given via intralesional injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given via intralesional injection
Study: NCT01790477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Application of auricular acupuncture to 5 points on the ear
Study: NCT00823810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: 18F-FDG PET/CT
Study: NCT01900951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide